EGFR and neoplasm: Postmenopausal women have the option of selecting raloxifene but, like tamoxifen, resistance to raloxifene also has been reported in experimental models.76 Raloxifene-resistant tumor cells demonstrated increased expression of both epidermal growth factor receptor (Egrf) (ERBB) and v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2).